From the Medicine Cabinet to the Black Market: China's 'Recycled Drug' Trade Exposed

The pills began their journey in a properly insured medicine cabinet, left it for cash, and came back into circulation as something worse. That round trip — known in China as "recycled drugs" (回流药) — is the subject of an investigation CCTV aired after the national medical-insurance system's data flagged the pattern in January, and the numbers behind it have now hit Baidu's trending board: since 2025, more than 62,000 institutions investigated and over 3 billion yuan involved.

The mechanism is simple and, until recently, hard to see. A drug dealer recruits people covered by China's basic medical insurance to buy prescription medicines at the heavily subsidized insured price — then buys the pills from them for cash and resells them at a markup. To make the secondhand stock look legitimate, dealers forged invoices and paperwork that "laundered" the drugs' origins. Everyone in the chain saves or earns a little; the cost lands twice — on the insurance fund that paid full freight for pills now circulating outside any legitimate supply chain, and on whoever eventually swallows one with no verified history.

That second cost is what the newest cases have made vivid. In Guangzhou, insurance authorities working with police dismantled a buy-and-resell gang and seized more than 8,000 boxes of medicine on the spot. The drugs in question were supposed to be stored in a cold chain — a chain that ran, in fact, through 30-plus-degree heat, the boxes later dressed in fake cold-chain packaging for shipment. The single largest drug involved was semaglutide, the injectable behind China's weight-loss boom, where demand has run so hot that the site covered the shot's side-effect economy a week ago. A drug with no cold chain is not a discount; it is a different, unlabelled product. For medicines that spoil invisibly, resale is indistinguishable from adulteration.

The enforcement answer is being built in software. The National Healthcare Security Administration now anchors its cases on drug traceability codes — unique identifiers scanned at each sale — and it was the insurance system itself that flagged the first anomalous leads in January. The 62,000 violating institutions reported since 2025 sit alongside the fraud cases China's regulators have been publishing all month: thirty drug firms, 184 million yuan in kickbacks to a single Hebei hospital among them. Different schemes, same source — the insurance fund, and the data exhaust it generates.

The recycled-drug trade thrived on a gap between two populations: the insured, for whom medicine is nearly free, and the uncovered, for whom it isn't. As traceability closes the resale route, the demand underneath it does not automatically vanish — it moves, as the chemo-drug shortage coverage showed, into calls to manufacturers and gray-market workarounds. The next metric to watch is not another headline number of busted institutions, but whether the black market's price for a secondhand box of semaglutide keeps rising as its supply dries up.